Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

Home Newsfeeds Dawson James Downgrades BioCardia to Neutral

Dawson James Downgrades BioCardia to Neutral

Dawson James analyst Jason Kolbert downgrades BioCardia (NASDAQ:BCDA) from Buy to Neutral.

byBenzinga Newsdesk

November 11, 2022

1 minute read

Dawson James analyst Jason Kolbert downgrades BioCardia (NASDAQ:BCDA) from Buy to Neutral.

Analyst Ratings

Analyst Expectations for Madrigal Pharmaceuticals’s Future

By Benzinga Insights

May 16, 1:01 PM

Within the last quarter, Madrigal Pharmaceuticals (NASDAQ:MDGL) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…

MDGL

Industry Comparison: Evaluating Copart Against Competitors In Commercial Services & Supplies Industry

By Benzinga Insights

January 12, 12:00 PM

In the ever-changing and fiercely competitive business landscape, conducting thorough company analysis is crucial for investors and industry…

CPRT

News
Tech

AOC Accuses Ford CEO Of Jacking Up Chief Exec. Pay To ‘Ludicrous Levels’ While ‘Starving The Workers’

By Ananya Gairola

September 16, 4:35 AM

Alexandria Ocasio-Cortez has criticized Jim Farley for increasing CEO pay without addressing worker concerns during the ongoing UAW strike.

Rivian ‘Best Positioned EV OEM’: Analyst Praises Long-Term Outlook, R2 Launch, With Short-Term Caution

By Chris Katje

April 18, 12:49 PM

Rivian Automotive gets a lowered price target from an analyst with questions lingering on demand for electric vehicles.

RIVN

Dawson James Downgrades BioCardia to Neutral

Related Posts

Analyst Expectations for Madrigal Pharmaceuticals’s Future

Industry Comparison: Evaluating Copart Against Competitors In Commercial Services & Supplies Industry

AOC Accuses Ford CEO Of Jacking Up Chief Exec. Pay To ‘Ludicrous Levels’ While ‘Starving The Workers’

Rivian ‘Best Positioned EV OEM’: Analyst Praises Long-Term Outlook, R2 Launch, With Short-Term Caution